Non Small Cell Lung Carcinoma
6 competing products in clinical development for Non Small Cell Lung Carcinoma.
Pipeline by Phase
Phase 23
Phase 33
All Products (6)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| 89Zr-Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | Recruiting | 42 |
| Pemetrexed + Carboplatin | Eli Lilly | Phase 3 | Completed | 40 |
| Nivolumab + Ipilimumab + Pemetrexed + Cisplatin + Carboplatin | Ono Pharmaceutical | Phase 3 | Completed | 40 |
| CBT124 + EU-sourced Avastin® + Carboplatin + Paclitaxel | Cipla | Phase 3 | UNKNOWN | 36 |
| Enzastaurin HCL | Eli Lilly | Phase 2 | Completed | 35 |
| E7389 28 Day Cycle + E7389 21 Day Cycle | Eisai | Phase 2 | Completed | 35 |